That’s right! REVERIE now has a cover, and you can read the first chapter over at Paste Magazine, courtesy of Eric Smith! Link below. Also, you can pre-order REVERIE! It’s up on Amazon, with more options to come soon.
Exclusive Cover Reveal + Excerpt: Inception Meets The Magicians in Ryan La Sala’s Reverie
About the cover
So you’ve seen it, right?
I’m in love. The depth. The shimmering glitz. The sense of tipping through a dimension that is unraveling around you…that sense of your perspective shifting…
I love it. I cannot wait for every other book to positively WILT when put aside this beauty. I’m kidding. I know it’s not like that, and I’m not that conceited. But I AM excited that REVERIE’s cover literally shines. If anything shall wither next to it, it’s going to be me. My face. I can’t compare to this! I don’t even sparkle a LITTLE bit.
Anyhow, let’s talk about the design:
It’s no secret that REVERIE covers….a lot of territory. There were many, MANY directions we could have gone in with the cover, some more obvious than others. This is why I am SO grateful for the team at Sourcebooks, and especially Nicole Hower (the incredible Art Director behind some of the most iconic covers out there) and Leo Nickolls (the hyper-talented artist).
For this cover, we wanted to capture an ethereal, unraveling magic within a sense of warping perspective. We wanted something that was bold, without feeling overly stark. We wanted something with depth, without feeling overly subtle.
Nicole and the Sourcebooks team did all these dreams justice, and then some. For instance I never dreamed my book would have…iridescent foil. Like. WHAT? Isn’t that illegal?
But let’s talk about rainbow foil, okay? REVERIE’s content is in dialogue with a lot of queer themes, and it was important to me that there be a visual indicator of this on the cover. But I wanted to approach this with SOME subtly. I’m acutely aware that the content of my book–specifically it’s unabashed centering of queerness–creates a risk for some readers. Readers who are reading in environments that carefully watch for flamboyance or eccentricity.
Those are the kids I think of most when I’m writing, so I wanted a design that evoked the mysterious power of many queer symbols: clear to queers, sparkly to everyone else. And that’s what this design is to me. It’s the right balance between conspicuous queerness and canon fantasy whimsy, and I dig the range.
Eventually, when the book is out, I’ll do a deeper dive into the symbolism of a few things in the design, but for now I hope you read the chapter and love it!
Rituximab (a humanized anti-CD20 monoclonal antibody) is a useful therapy
for Epstein-Barr virus-related publish transplant lymphoproliferative disease (EBV-PTLD).
Nonetheless, hypogammaglobulinemia is a complication associated with this remedy.1,2 Little is
understood concerning the duration and severity of
rituximab-induced low serum immunoglobulin (Ig) status.
EBV-PTLD. Considered one of three patients reported by Verschuuren et al1
died of invasive aspergillosis as a result of hypogammaglobulinemia after 7 months of rituximab therapy.
Tax calculation will be finalised during checkout.
Get time restricted or full article access on ReadCube.
All prices are Web prices. Verschuuren EA, Stevens SJ,
van Imhoff GW et al. Therapy of posttransplant lymphoproliferative disease with
rituximab: the remission, the relapse, and the complication. Quartier P,
Brethon B, Philippet P et al. Treatment of childhood autoimmune haemolytic
anaemia with rituximab. Castagnola E, Dallorso S, Faraci M et al.
Lengthy-lasting hypogammaglobulinemia following rituximab administration for Epstein-Barr virus-associated post-transplant lymphoproliferative disease preemptive therapy.
Imashuku S, Naya M, Tamura S et al. Effectiveness of rituximab for chemotherapy-resistant a number of tumoral B-LPD in a haematopoietic
stem cell recipient. Faye A, Quartier P, Reguerre Y et al.
Chimaeric anti-CD20 monoclonal antibody (rituximab) in submit-transplant B-lymphoproliferative disorder following stem cell transplantation in kids.
Esser JWJ, Niesters HGM, van der Holt B et al. Prevention of Epstein-Barr virus-lymphoproliferative
illness by molecular monitoring and preemptive rituximab in excessive-danger patients after allogeneic stem cell transplantation. Kuehnle I, Huls MH, Liu Z et al.
CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus
lymphoma after hemopoietic stem cell transplantation. Imashuku, S., Teramura, T., Morimoto, A.
et al. Extended hypogammaglobulinemia following rituximab treatment for post transplant
Epstein-Barr virus-related lymphoproliferative illness.